FR2896161B1 - Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique. - Google Patents

Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.

Info

Publication number
FR2896161B1
FR2896161B1 FR0600347A FR0600347A FR2896161B1 FR 2896161 B1 FR2896161 B1 FR 2896161B1 FR 0600347 A FR0600347 A FR 0600347A FR 0600347 A FR0600347 A FR 0600347A FR 2896161 B1 FR2896161 B1 FR 2896161B1
Authority
FR
France
Prior art keywords
healing
medicament
manufacturing
triazine derivatives
angiogenic effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0600347A
Other languages
English (en)
French (fr)
Other versions
FR2896161A1 (fr
Inventor
Gerard Moinet
Daniel Cravo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sante SAS
Original Assignee
Merck Sante SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0600347A priority Critical patent/FR2896161B1/fr
Application filed by Merck Sante SAS filed Critical Merck Sante SAS
Priority to KR1020087019389A priority patent/KR101482686B1/ko
Priority to DK06829704.3T priority patent/DK1971329T3/en
Priority to CA2636838A priority patent/CA2636838C/en
Priority to SI200632225T priority patent/SI1971329T1/en
Priority to AU2006334732A priority patent/AU2006334732B2/en
Priority to EP06829704.3A priority patent/EP1971329B1/en
Priority to BRPI0620983A priority patent/BRPI0620983B8/pt
Priority to PL06829704T priority patent/PL1971329T3/pl
Priority to PT68297043T priority patent/PT1971329T/pt
Priority to EA200801678A priority patent/EA016127B1/ru
Priority to JP2008549781A priority patent/JP2009523140A/ja
Priority to ES06829704.3T priority patent/ES2647912T3/es
Priority to HUE06829704A priority patent/HUE037217T2/hu
Priority to LTEP06829704.3T priority patent/LT1971329T/lt
Priority to US12/160,515 priority patent/US8217040B2/en
Priority to CNA200680050807XA priority patent/CN101355931A/zh
Priority to PCT/EP2006/012183 priority patent/WO2007079915A2/en
Priority to ARP070100140A priority patent/AR059034A1/es
Publication of FR2896161A1 publication Critical patent/FR2896161A1/fr
Application granted granted Critical
Publication of FR2896161B1 publication Critical patent/FR2896161B1/fr
Priority to IL192595A priority patent/IL192595A/en
Priority to ZA200806946A priority patent/ZA200806946B/xx
Priority to CY20171101240T priority patent/CY1119872T1/el
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FR0600347A 2006-01-13 2006-01-13 Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique. Expired - Fee Related FR2896161B1 (fr)

Priority Applications (22)

Application Number Priority Date Filing Date Title
FR0600347A FR2896161B1 (fr) 2006-01-13 2006-01-13 Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.
HUE06829704A HUE037217T2 (hu) 2006-01-13 2006-12-18 Triazinszármazékok sebgyógyító kezelésben történõ alkalmazásra
CA2636838A CA2636838C (en) 2006-01-13 2006-12-18 Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect
SI200632225T SI1971329T1 (en) 2006-01-13 2006-12-18 Triazine derivatives for use in the treatment of cicatrization
AU2006334732A AU2006334732B2 (en) 2006-01-13 2006-12-18 Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect
EP06829704.3A EP1971329B1 (en) 2006-01-13 2006-12-18 Triazine derivatives for use in a cicatrising treatment
BRPI0620983A BRPI0620983B8 (pt) 2006-01-13 2006-12-18 uso de derivados de triazina para fabricação de um medicamento, e composição farmacêutica para uso tópico
PL06829704T PL1971329T3 (pl) 2006-01-13 2006-12-18 Pochodne triazyny do stosowania do leczenia zabliźniającego
PT68297043T PT1971329T (pt) 2006-01-13 2006-12-18 Derivados de triazina para utilização num tratamento cicatrizante
DK06829704.3T DK1971329T3 (en) 2006-01-13 2006-12-18 TRIAZIN DERIVATIVES FOR USE IN A CICATRICIAL TREATMENT
JP2008549781A JP2009523140A (ja) 2006-01-13 2006-12-18 瘢痕形成または血管形成効果を有する医薬の製造のためのトリアジン誘導体の使用
ES06829704.3T ES2647912T3 (es) 2006-01-13 2006-12-18 Derivados de triazina para uso en un tratamiento de cicatrización
KR1020087019389A KR101482686B1 (ko) 2006-01-13 2006-12-18 상처치유 또는 혈관생성 효과를 갖는 약제의 제조를 위한트리아진 유도체의 용도
LTEP06829704.3T LT1971329T (lt) 2006-01-13 2006-12-18 Triazino dariniai, skirti naudoti surandėjimo gydymui
EA200801678A EA016127B1 (ru) 2006-01-13 2006-12-18 Применение производных триазина для производства лекарственного средства, обладающего заживляющим или ангиогенным эффектом
CNA200680050807XA CN101355931A (zh) 2006-01-13 2006-12-18 三嗪衍生物在制备具有愈合或血管生成作用的药物中的用途
PCT/EP2006/012183 WO2007079915A2 (en) 2006-01-13 2006-12-18 Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect
US12/160,515 US8217040B2 (en) 2006-01-13 2006-12-18 Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect
ARP070100140A AR059034A1 (es) 2006-01-13 2007-01-12 Uso de derivados de triazina para la fabricacion de un medicamento que tiene un efecto cicatrizante y/o angiogenico
IL192595A IL192595A (en) 2006-01-13 2008-07-02 Use of triazine derivatives to make a drug that has a blood vessel formation effect or a scar tissue effect
ZA200806946A ZA200806946B (en) 2006-01-13 2008-08-12 Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect
CY20171101240T CY1119872T1 (el) 2006-01-13 2017-11-27 Παραγωγα τριαζινης προς χρηση σε μια επουλωτικη θεραπευτικη αγωγη

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0600347A FR2896161B1 (fr) 2006-01-13 2006-01-13 Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.

Publications (2)

Publication Number Publication Date
FR2896161A1 FR2896161A1 (fr) 2007-07-20
FR2896161B1 true FR2896161B1 (fr) 2008-04-04

Family

ID=36658622

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0600347A Expired - Fee Related FR2896161B1 (fr) 2006-01-13 2006-01-13 Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.

Country Status (22)

Country Link
US (1) US8217040B2 (enExample)
EP (1) EP1971329B1 (enExample)
JP (1) JP2009523140A (enExample)
KR (1) KR101482686B1 (enExample)
CN (1) CN101355931A (enExample)
AR (1) AR059034A1 (enExample)
AU (1) AU2006334732B2 (enExample)
BR (1) BRPI0620983B8 (enExample)
CA (1) CA2636838C (enExample)
CY (1) CY1119872T1 (enExample)
DK (1) DK1971329T3 (enExample)
EA (1) EA016127B1 (enExample)
ES (1) ES2647912T3 (enExample)
FR (1) FR2896161B1 (enExample)
HU (1) HUE037217T2 (enExample)
IL (1) IL192595A (enExample)
LT (1) LT1971329T (enExample)
PL (1) PL1971329T3 (enExample)
PT (1) PT1971329T (enExample)
SI (1) SI1971329T1 (enExample)
WO (1) WO2007079915A2 (enExample)
ZA (1) ZA200806946B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2948027A1 (fr) * 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
JP2020536121A (ja) 2017-10-02 2020-12-10 ポクセルＰｏｘｅｌ 駆出率が保持された心不全を治療する方法
CA3102412A1 (en) 2018-06-06 2019-12-12 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
WO2019238647A1 (en) 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
EP4014962A1 (de) * 2020-12-16 2022-06-22 Novigo GmbH & Co. KG Zusammensetzung mit osmotisch wirksamer substanz und verwendung der zusammensetzung
FR3149774B1 (fr) * 2024-01-11 2025-06-20 Fabre Pierre Dermo Cosmetique 5,6,5’,6’-tétraphényl-3,3’-(1,4-phénylène)-bis[1,2,4]triazine pour améliorer l’aspect des cicatrices et/ou réduire les marques cicatricielles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150362A (en) * 1997-12-12 2000-11-21 Henkin; Jack Triazine angiogenesis inhibitors
DK1037886T3 (da) * 1997-12-12 2003-08-25 Abbott Lab Triazin angiogeneseinhibitorer
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
AU2003289375A1 (en) * 2002-12-17 2004-07-09 Hamari Chemicals, Ltd Novel 2,4-diamino-1,3,5-triazine derivative
FR2853650B1 (fr) * 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance

Also Published As

Publication number Publication date
SI1971329T1 (en) 2018-03-30
WO2007079915A2 (en) 2007-07-19
BRPI0620983B8 (pt) 2021-05-25
JP2009523140A (ja) 2009-06-18
ZA200806946B (en) 2009-11-25
BRPI0620983A2 (pt) 2011-11-29
AU2006334732B2 (en) 2012-05-17
CN101355931A (zh) 2009-01-28
EP1971329A2 (en) 2008-09-24
CA2636838A1 (en) 2007-07-19
PT1971329T (pt) 2017-11-24
ES2647912T3 (es) 2017-12-27
PL1971329T3 (pl) 2018-03-30
EP1971329B1 (en) 2017-10-11
HUE037217T2 (hu) 2018-08-28
AR059034A1 (es) 2008-03-12
EA200801678A1 (ru) 2008-12-30
EA016127B1 (ru) 2012-02-28
DK1971329T3 (en) 2017-12-04
KR101482686B1 (ko) 2015-01-14
BRPI0620983B1 (pt) 2019-09-17
LT1971329T (lt) 2018-01-25
WO2007079915A3 (en) 2007-08-30
IL192595A0 (en) 2009-02-11
IL192595A (en) 2013-04-30
US20100168115A1 (en) 2010-07-01
CA2636838C (en) 2015-05-05
FR2896161A1 (fr) 2007-07-20
US8217040B2 (en) 2012-07-10
AU2006334732A1 (en) 2007-07-19
KR20080088629A (ko) 2008-10-02
CY1119872T1 (el) 2018-06-27

Similar Documents

Publication Publication Date Title
NO2025029I1 (no) Entrectinib or isomers, tautomers, or pharmaceutically acceptable salts therof - forlenget
NO2022015I1 (no) Tepotinib and pharmaceutically usable solvates, salts, tautomers and stereoisomers thereof
FR15C0029I2 (fr) Inhibiteurs de la tyrosine kinase de bruton
ES2590905T8 (es) Inhibidores de la tirosina quinasa de Bruton
ES2352576T8 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana.
LTC1830843I2 (lt) Indolidono dariniai, skirti fibrozinių ligų gydymui arba prevencijai
BRPI0810086A2 (pt) inibidores de tirosina quinase de bruton
BRPI0915105A2 (pt) composto de 2,4'-biripidinila como inibidores da proteína cinase d úteis para o tratamento de ia insuficiência cardíaca e cancer
BRPI1013153A2 (pt) solução de bloqueio do cateter tendo propriedades antimicrobiana e anticoagulante.
WO2007114926A3 (en) Kinase antagonists
DK1907037T3 (da) Medikamentdispenser.
EP2305862A4 (en) ENVIRONMENTALLY FRIENDLY ABSORBENT DISHWASHER
SE0700888L (sv) Alkaliska massaberedningsprocesser och -system för lövved
GB0912562D0 (en) LXR-antagonists for the prevention, reduction or inhibition of scarring
BRPI0906495A2 (pt) Derivados de indolol-piridona tendo atividade inibidora de quinase de ponto de checagem 1
DE502006002276D1 (de) Integriertes medizinisches Trackingsystem
ZA200806946B (en) Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect
EP2000171A4 (en) MEDICAL SHUTTER
BRPI0820964A2 (pt) Oxazolidinonas para o tratamento e/ou profilaxia de insuficiência cardíaca
BRPI0812175A2 (pt) Fechadura de cinto de segurança com amortecimento de som
CL2007003162A1 (es) Uso de compuestos derivados de vitamina d para prevenir, tratar o aminorar un desorden hiperproliferativo.
WO2011033115A3 (en) Compounds useful against kinetoplastideae parasites
BRPI0913586A2 (pt) combinação, uso de combinação, método para tratar, inibir ou prevenir uma doença ou condição.
FR2896158B1 (fr) Combinaison de derives de triazine et d'inhibiteurs de la hmg-coa reductase.
BRPI0721725A2 (pt) Preparação de derivados semi-sintéticos e bioativos, a partir de 4-nerolidilcatecol e dilapiol.

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

ST Notification of lapse

Effective date: 20220905